|
Sleep Apnea, Central
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study aims to examine <i>COMT</i> Val158Met (rs4680) and <i>BDNF</i> Val66Met (rs6265) polymorphisms in CSA.
|
31142902 |
2020 |
|
Conduct Disorder
|
|
0.010 |
GeneticVariation
|
BEFREE |
Effects of BDNF Val66Met polymorphisms on brain structures and behaviors in adolescents with conduct disorder.
|
31264106 |
2020 |
|
Neurodevelopmental Disorders
|
|
0.010 |
GeneticVariation
|
BEFREE |
The Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) has emerged as a high-interest genetic variant due to its importance in cortical maturation, and several studies have implicated its involvement in neurodevelopmental disorders.
|
31264106 |
2020 |
|
Cockayne Syndrome, Type I
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study aims to examine <i>COMT</i> Val158Met (rs4680) and <i>BDNF</i> Val66Met (rs6265) polymorphisms in CSA.
|
31142902 |
2020 |
|
Optic Neuritis
|
|
0.010 |
GeneticVariation
|
BEFREE |
These findings suggest that the BDNF Val66Met polymorphism may be associated with optic nerve damage caused by acute ON attacks in NMOSD patients.
|
31803011 |
2019 |
|
Psychological symptom
|
|
0.010 |
GeneticVariation
|
BEFREE |
Neither BDNF Val66Met nor IL-6 G174C were linked to psychological symptoms.
|
31132388 |
2019 |
|
Large-artery atherosclerosis (embolus/thrombosis)
|
|
0.010 |
GeneticVariation
|
BEFREE |
The AA genotype at the rs6265 locus was associated with the occurrence of ischemic stroke in patients with large-artery atherosclerosis (OR = 0.58; 95% CI: 0.37-0.90; P = 0.015).
|
30964066 |
2019 |
|
Glaucoma, Open-Angle
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, the fact that this effect is observed only in females indicates BDNF Val66Met influences the progression rate of OAG in a sex-specific manner.
|
30897622 |
2019 |
|
Overweight and obesity
|
|
0.010 |
GeneticVariation
|
BEFREE |
The BDNF rs6265 variant may interact with overweight and obesity to influence obesity-related physical, metabolic and behavioural traits in Pakistani individuals.
|
30590963 |
2019 |
|
Fetal Alcohol Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
These studies show that the BDNF val66met polymorphism modulates, in a complex manner, the effects of developmental EtOH exposure, and identify a novel genetic risk factor that may regulate FASDs severity in humans.
|
29691979 |
2019 |
|
Cerebral atrophy
|
|
0.010 |
GeneticVariation
|
BEFREE |
The BDNF Val66Met polymorphism is associated with cognitive impairment and brain atrophy among the non-demented elderly, APOEɛ4 non-carriers and A + subgroup, implying the potential of the Val66Met polymorphism as an important genetic factor for AD-related neurodegeneration.
|
30775992 |
2019 |
|
Liver carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haplotype GA of rs6265 and G11757C increased the risk of PTSD for HCC, while haplotype CG decreased this risk.
|
30659644 |
2019 |
|
Focal Dystonia
|
|
0.010 |
GeneticVariation
|
BEFREE |
While the pathophysiology and genetic susceptibility in BSP and focal dystonia are only partially understood, it seems that BDNF and rs6265 may constitute one essential risk factor that is heavily involved.
|
30519954 |
2019 |
|
Autistic Disorder
|
|
0.010 |
GeneticVariation
|
BEFREE |
No significant interaction between the rs6265 genotype and autism was observed for the BDNF expression.
|
29935919 |
2019 |
|
Childhood Non-Hodgkin Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We have evaluated the peripheral blood protein levels of BDNF and the valine-to-methionine substitution at codon 66 (Val66Met) single-nucleotide polymorphism (SNP) as potential biomarkers for the early recognition of chemotherapy-induced peripheral neuropathy (CIPN) in non-Hodgkin lymphoma and multiple myeloma patients.
|
31591840 |
2019 |
|
Lymphoma, Non-Hodgkin, Familial
|
|
0.010 |
GeneticVariation
|
BEFREE |
We have evaluated the peripheral blood protein levels of BDNF and the valine-to-methionine substitution at codon 66 (Val66Met) single-nucleotide polymorphism (SNP) as potential biomarkers for the early recognition of chemotherapy-induced peripheral neuropathy (CIPN) in non-Hodgkin lymphoma and multiple myeloma patients.
|
31591840 |
2019 |
|
Lymphoma, Non-Hodgkin
|
|
0.010 |
GeneticVariation
|
BEFREE |
We have evaluated the peripheral blood protein levels of BDNF and the valine-to-methionine substitution at codon 66 (Val66Met) single-nucleotide polymorphism (SNP) as potential biomarkers for the early recognition of chemotherapy-induced peripheral neuropathy (CIPN) in non-Hodgkin lymphoma and multiple myeloma patients.
|
31591840 |
2019 |
|
Neuromyelitis Optica
|
|
0.010 |
GeneticVariation
|
BEFREE |
These findings suggest that the BDNF Val66Met polymorphism may be associated with optic nerve damage caused by acute ON attacks in NMOSD</span> patients.
|
31803011 |
2019 |
|
Multiple Myeloma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We have evaluated the peripheral blood protein levels of BDNF and the valine-to-methionine substitution at codon 66 (Val66Met) single-nucleotide polymorphism (SNP) as potential biomarkers for the early recognition of chemotherapy-induced peripheral neuropathy (CIPN) in non-Hodgkin lymphoma and multiple myeloma patients.
|
31591840 |
2019 |
|
Sexual Dysfunction
|
|
0.010 |
GeneticVariation
|
BEFREE |
The present study aimed to determine the relationship between serotonin-2A receptor (HTR2A) gene -1438A/G and 102T/C polymorphisms, serotonin transporter gene (SLC6A4) 5-HTT-linked polymorphic region (5-HTTLPR) insertion/deletion variant and brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphisms and the occurrence of SD adverse effect in major depressive disorder patients treated with citalopram (CIT) or sertraline (SERT).
|
31792367 |
2019 |
|
Aphasia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Utilizing data from our recently completed trial, we conducted a planned test of whether aphasia treatment outcome is influenced by interaction between A-tDCS and a single-nucleotide polymorphism of the BDNF gene, rs6265.
|
30150003 |
2019 |
|
Brain atrophy
|
|
0.010 |
GeneticVariation
|
BEFREE |
The BDNF Val66Met polymorphism is associated with cognitive impairment and brain atrophy among the non-demented elderly, APOEɛ4 non-carriers and A + subgroup, implying the potential of the Val66Met polymorphism as an important genetic factor for AD-related neurodegeneration.
|
30775992 |
2019 |
|
Fetal Alcohol Spectrum Disorders
|
|
0.010 |
GeneticVariation
|
BEFREE |
These studies show that the BDNF val66met polymorphism modulates, in a complex manner, the effects of developmental EtOH exposure, and identify a novel genetic risk factor that may regulate FASDs severity in humans.
|
29691979 |
2019 |
|
Obesity, Morbid
|
|
0.010 |
GeneticVariation
|
BEFREE |
BDNF Val66Met genetic variation and its plasma level in patients with morbid obesity: A case-control study.
|
31004714 |
2019 |
|
Adult Non-Hodgkin Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We have evaluated the peripheral blood protein levels of BDNF and the valine-to-methionine substitution at codon 66 (Val66Met) single-nucleotide polymorphism (SNP) as potential biomarkers for the early recognition of chemotherapy-induced peripheral neuropathy (CIPN) in non-Hodgkin lymphoma and multiple myeloma patients.
|
31591840 |
2019 |